



POSTER SESSIONS

5TH CCBIO ANNUAL SYMPOSIUM 2017

POSTER SESSION DAY 1, APRIL 19TH 2017

1. **Investigation of α SMA expression in p16 and p53 positive Oral Cancer.**
Presenter: Ahmed Israa
2. **Generation and Characterization of integrin ITGA11-Cre mouse strain.**
Presenter: Jahedul Alam.
3. **Preclinical Imaging in High Grade Serous Ovarian Cancer Cell Line Based Mouse Models: A Comparative Study.**
Presenter: Shamundeeswari Anandan.
4. **Proteomic profiling of breast cancer patient samples, cell lines and conditioned media.**
Presenter: Even Birkeland.
5. **The impact of tumor interstitial fluid pressure on nanoparticle accumulation by cAMP receptors modulation.**
Presenters: Ronja Bjørnstad and Sarah Marie Vie Furevik.
6. **The effects of metformin treatment in colorectal cancer cells of opposing metabolic phenotype.**
Presenter: Ansooya Bokil and Abdelnour Alhourani.
7. **Establishment of humanised immune system mice for evaluation of immunotherapies in patient derived xenograft tumour models.**
Presenter: Geir Bredholt.
8. **The mitochondrial succinate dehydrogenase complex is an important regulator of epithelial to mesenchymal transition.**
Presenter: Sissel Dyrstad.
9. **Functional MRI predicts aggressive disease in endometrial cancer.**
Presenter: Kristine Fasmer.



POSTER SESSION DAY 1, APRIL 19TH 2017

10. **Validation of Asparaginase like protein 1 (ASRGL1) as Prognostic Biomarker in Endometrial Carcinoma.**
Presenter: Tina Fonnes.
11. **FOXA1 predicts good outcome in HER2+ endometrial cancer patients by inhibiting EGFR/HER2 signaling.**
Presenter: Mari Halle.
12. **AKT3 subcellular localization and signaling modulates tumorigenicity**
Presenter: Stefan Hinz
13. **Novel STAT3 inhibitors targeting the STAT3 dimerization.**
Presenter: Yaping Hua.
14. **Prognostic impact and concordance of TERT promoter mutation and protein expression in primary and matched secondary cutaneous melanomas.**
Presenter: Emilia Hugdahl.
15. **MicroRNA signature as a potential biomarker for predicting recurrence in colon cancer.** Presenter: Havjin Jacob.
16. **Trimodal pilot study of neo-adjuvant regional hyperthermia, chemotherapy and radiotherapy in locally advanced, high-grade soft tissue sarcoma.**
Presenter: Nina Louise Jebsen.
17. **The Role of Axl Signaling in Tumor Metastasis and Anti-tumor Immune Evasion.**
Presenter: Jing Kang.
18. **Exploration of Novel Therapeutic Options in Mantle Cell Lymphoma.**
Presenter: Ida Karlsen.
19. **Angiogenic proteins are overrepresented in the hypoxic secretome from basal-like breast cancer cell lines.**
Presenter: Silje Kjølle.
20. **Oxygen-dependent regulation of tumour growth and metastasis in human breast cancer xenografts.**
Presenter: Maria Tveitarås.
21. **A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma.**
Presenter: Oddbjørn Straume.



POSTER SESSION DAY 2, APRIL 20TH 2017

22. **Optimization of human tumor dissociation to enhance engraftment rates in ovarian cancer patient derived xenograft models.**
Presenter: Katrin Kleinmanns.
23. **Single–Cell mRNA profiling reveals Transcriptional Hetero-geneity among Pancreatic Circulating Tumour Cells.**
Presenter: Morten Lapin.
24. **Inhibition of Axl abrogates the autophagic flux in NSCLC cells with acquired erlotinib resistance and induces immunogenic cell death.**
Presenter: Maria Lie.
25. **Optimization of bacterial DNA extraction protocol from saliva of Sudanese oral squamous cell carcinoma patients.**
Presenter: Nuha Mohamed.
26. **Head and neck cancer detection using an electronic nose device: results from a pilot study on Sudanese patients.**
Presenter: Nazar Gafar Mohamed.
27. **Comparison of two isogenic non-tumorigenic and tumorigenic breast epithelial-derived cell lines with mesenchymal phenotype.**
Presenter: Erika Morera Mojonero.
28. **The NOSARC project, a national, prospective and population-based study of mutations and mechanisms in sarcomas, and preclinical validation of novel targeted therapies, with the Intention to lead clinical trials.**
Presenter: Ola Myklebost.
29. **The good drug, the bad barrier and the handy peptide: K16ApoE improves the treatment of experimental brain metastases.**
Presenter: Synnøve Nymark Aasen.
30. **Predictive biomarkers in sunitinib treatment of metastatic renal cell carcinoma.**
Presenter: Martin Pilskog.
31. **Microvascular proliferation is associated with aggressive tumor features and reduced survival in lung adenocarcinomas.**
Presenter: Maria Ramnefjell.



POSTER SESSION DAY 2, APRIL 20TH 2017

32. **Development of a molecular diagnostic tool for more precise diagnosis of oral squamous cell carcinoma.**
Presenter: Martha Rolland Jacobsen.
33. **Indirect role of fibroblast Ext1 in regulating P311 expression in A549 carcinoma cells.**
Presenter: Lawrence Fred Sembajwe.
34. **Heterotypic interactions between endothelial cells and normal- and cancerous breast epithelial cells.**
Presenter: Sophie Steinhäuser.
35. **Molecular characterization of MPA/DMBA induced mouse mammary tumors.**
Presenter: Therese Sørli.
36. **Expression of L1CAM in curettage and high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients.**
Presenter: Ingvild Løberg Tangen.
37. **Axonogenesis and vascular proliferation are associated gene expression programs in hormone receptor negative breast cancer.**
Presenter: Elisabeth Wik.
38. **BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models.**
Presenter: Katarzyna Wnuk-Lipinska.